The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
A Systematic Review of the Efficacy of Domperidone for the Treatment of Diabetic Gastroparesis
Open accessAbstract
Background & aims Despite being widely used in more than 20 countries for the treatment of diabetic gastroparesis for several decades, domperidone is approved only on an investigational basis in the United States. However, because its use is increasing, it is important for gastroenterologists in this country to understand its effectiveness in this condition. The literature on this subject varies considerably with respect to the methods and outcome measures, making a meta-analysis unfeasible.Methods Our objective was to systematically analyze studies of the efficacy of domperidone in diabetic gastroparesis, with a focus on their methodologic and scientific merit. Information from 28 trials (11 full articles and 17 abstracts) from 1981 to 2007 was analyzed.Results The average study quality score was 8.3 out of a possible 15 and the total sample size equaled 1016. Overall, 64% of the studies showed significant efficacy of domperidone on the improvement of symptoms. Sixty percent of the studies showed an efficacy in gastric emptying and 67% of the studies proved the drug effective in reducing hospital admissions.Conclusions Overall, our assessment is that there is level 3 evidence for the efficacy of domperidone in diabetic gastroparesis, leading to a grade C recommendation for its use in this condition. These results need to be interpreted very cautiously because of significant methodologic limitations of these studies, including the fact that most positive studies lacked a control arm. It is clear that larger and better-designed studies are needed to further validate the use of this drug in diabetic gastroparesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Domperidone, another D2-antagonist, has much less penetration through the blood-brain barrier when compared to metoclopramide. In use throughout the world, it has not been approved by the FDA, because of unconvincing efficacy data, although it possesses a good safety profile [61].”
From Gastrointestinal symptoms in postural tachycardia syndrome: a systematic review (2018) · cites this paper as [61]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Current methods of the U.S. Preventive Services Task Force
Harris, R., Helfand, M., Woolf, S. H., Lohr, K. N., Mulrow, C. D., Teutsch, S. M., & Atkins, D. C. (2001) · American Journal of Preventive Medicine · doi:10.1016/s0749-3797(01)00261-6 · Cited by 1,720
Koch, K. L., Stern, R. M., Stewart, W. R., & Vasey, M. W. (1989) · PubMed · Cited by 324
Domperidone: Review of Pharmacology and Clinical Applications in Gastroenterology
Reddymasu, S. C., Soykan, I., & McCallum, R. W. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01255.x · Cited by 304
Patterson, D., Abell, T., Rothstein, R., Koch, K., & Barnett, J. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.00456.x · Cited by 266
Domperidone: A Peripherally Acting Dopamine 2 -Receptor Antagonist
Barone, J. A. (1999) · Annals of Pharmacotherapy · doi:10.1345/aph.18003 · Cited by 260
Gastric emptying in patients with diabetes mellitus.
Loo, F. D., Palmer, D., Soergel, K., Kalbfleisch, J., & Wood, C. M. (1984) · Gastroenterology · doi:10.1016/s0016-5085(84)80019-0 · Cited by 254
Acute and chronic effects of domperidone on gastric emptying in diabetic autonomic neuropathy
Horowitz, M., Harding, P. E., Chatterton, B. E., Collins, P., & Shearman, D. J. C. (1985) · Digestive Diseases and Sciences · doi:10.1007/bf01318363 · Cited by 233
Patterson, D. (1999) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(98)00337-2 · Cited by 152
Silvers, D. S., Kipnes, M. S., Broadstone, V. L., Patterson, D., Quigley, E. M. M., McCallum, R. W., Leidy, N. K., Farup, C. E., Liu, Y., & Joslyn, A. F. (1998) · Clinical Therapeutics · doi:10.1016/s0149-2918(98)80054-4 · Cited by 141
Soykan, İ., Sarosiek, I., & McCallum, R. W. (1997) · PubMed · Cited by 119
Vittal, H., Farrugia, G., Gomez, G., & Pasricha, P. J. (2007) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep0838 · Cited by 109
Self-citationThe role of prolactin and growth hormone in breast cancer
Wennbo, H., & Törnell, J. (2000) · Oncogene · doi:10.1038/sj.onc.1203349 · Cited by 107
Dhir, R., & Richter, J. (2004) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-200403000-00008 · Cited by 88
Domperidone is more effective than cisapride in children with diabetic gastroparesis
Franzese, A., Borrelli, O., Corrado, G., Rea, P., Nardo, G. D., Grandinetti, A., Dito, L., & Cucchiara, S. (2002) · Alimentary Pharmacology and Therapeutics · doi:10.1046/j.1365-2036.2002.01240.x · Cited by 77
Insulin Administration Enhances Growth of the β-Cell Mass in Streptozotocin-Treated Newborn Rats
Movassat, J., Saulnier, C., & Portha, B. (1997) · Diabetes · doi:10.2337/diab.46.9.1445 · Cited by 75
Current Concepts in Diabetic Gastroparesis
Smith, D. S., & Ferris, C. D. (2003) · Drugs · doi:10.2165/00003495-200363130-00002 · Cited by 68
Making a case for domperidone in the treatment of gastrointestinal motility disorders
AHMAD, N., KEITHFERRIS, J., GOODEN, E., & Abell, T. L. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.07.004 · Cited by 68
An evidence-based approach to gastroenterology therapy
Schoenfeld, P., Cook, D., Hamilton, F. A., Laine, L., Morgan, D. J., & Peterson, W. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70439-1 · Cited by 57
Domperidone versus metoclopramide in the treatment of diabetic gastroparesis
Dumitraşcu, D., & Weinbeck, M. (2000) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.01721.x · Cited by 50
Diabetic gastroparesis: treatment with domperidone--a double-blind, placebo-controlled trial.
Heer, M., Müller-Duysing, W., Benes, I., Weitzel, M., Pirovino, M., Altorfer, J., & Schmid, M. K. (1983) · Digestion · doi:10.1159/000198955 · Cited by 43
Nagler, J., & Miskovitz, P. F. (1981) · PubMed · Cited by 38
Management of Idiopathic, Diabetic and Miscellaneous Gastroparesis with Cisapride
Champion, M. C. (1989) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365528909091230 · Cited by 25
Treatment of Diabetic Gastroparesis with Oral Domperidone
Watts, G. F., Armitage, M., Sinclair, J., & Hill, R. (1985) · Diabetic Medicine · doi:10.1111/j.1464-5491.1985.tb00689.x · Cited by 25
Does combination prokinetic therapy benefit patients with refractory diabetic gastroparesis?
Lehmann, K., & Patterson, D. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)26858-8 · Cited by 4
Increase in Mammographic Breast Density Associated with the Use of Domperidone
Harvey, J. A., Cowan, J. H., & LoRusso, A. P. (2004) · The Breast Journal · doi:10.1111/j.1075-122x.2004.21441.x · Cited by 3
(1995) · Gastroenterology · doi:10.1016/0016-5085(95)22804-7 · Cited by 2
Flagged first, then by citations
Research works printed but not linked: 12
- Braun, 1989, Domperidone in the treatment of symptoms of delayed gastric emptying in diabetic patients, Adv Ther, 6, 51
- Kozarek, 1990, Domperidone for symptomatic management of diabetic gastroparesis in metoclopramide treatment failures, Adv Ther, 7, 61
- Stern, 1989, Summary of the 34th meeting of the Food and Drug Administration Gastrointestinal Drugs Advisory Committee, Am J Gastroenterol, 84, 1351
- Bingaman, 1997, Long-term domperidone treatment for symptoms of gastroparesis in diabetic patients, Diabetes, 46, 1204
- Miller, 1991, Natural history of diabetic gastroparesis treated with cisapride or domperidone, Am J Gastroenterol, 86, 1316
- Patterson, 1991, Domperidone is effective long-term treatment for diabetic gastroparesis, Gastroenterology, 100, A137
- Patterson, 1993, A multicenter placebo-controlled study of domperidone in diabetic gastroparesis, Gastroenterology, 104, A564
- Patterson, 1997, Long-term efficacy of domperidone in patients with diabetes and symptoms of gastroparesis, Diabetes, 46, 490
- Koch, 1995, Withdrawal study of domperidone vs placebo in diabetic patients: effect on upper gastrointestinal symptoms and gastric myoelectrical activity, Gastroenterology, 108, A630, 10.1016/0016-5085(95)26831-6 · DOI
- Abell, 1997, Autonomic function is a determinant of quality of life improvement in response to domperidone therapy, Diabetes, 46, 1445
- Champion, 1991, Domperidone compared to cisapride in the management of gastroparesis, Am J Gastroenterol, 86, 1309
- Champion, 1987, Domperidone improves symptoms and solid phase gastric emptying in diabetic gastroparesis, Am J Gastroenterol, 82, 975
Cited by
Sorted by citations
11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc19-s011 · Cited by 416
“romycin, which is only effective for short-term use due to tachyphylaxis (141,142).”
Background11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s011 · Cited by 395
“) and erythromycin, which is only effective for short-term use due to tachyphylaxis (174,175).”
Background11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes−2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s011 · Cited by 460
“) and erythromycin, which is only effective for short-term use due to tachyphylaxis (167,168).”
BackgroundGastric emptying and glycaemia in health and diabetes mellitus
Phillips, L. K., Deane, A. M., Jones, K. L., Rayner, C. K., & Horowitz, M. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.202 · Cited by 273
12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2024
ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gibbons, C. H., Giurini, J. M., Hilliard, M. E., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc24-s012 · Cited by 259
Metadata
- Authors
- Sugumar, A., Singh, A., & Pasricha, P. J.
- Affiliations
- Mayo Clinic (US)
- The University of Texas Medical Branch at Galveston (US)
- Stanford Medicine (US)
- Corresponding author
- Pasricha, Pankaj Jay
- ORCID
- Pasricha, Pankaj Jay
- Venue
- Clinical Gastroenterology and Hepatology
- Publisher
- Elsevier BV
- Published
- 2008-07
- Volume
- 6
- Issue
- 7
- Pages
- 726-733
- ISSN
- 1542-3565 (ISSN-L)
- OpenAlex
- W2069589846
- Cited by
- 102
- References
- 28
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 1 · 2023: 8 · 2022: 6 · 2021: 5 · 2020: 2 · 2019: 4 · 2018: 5 · 2017: 8 · 2016: 9 · 2015: 5 · 2014: 8 · 2013: 7 · 2012: 13
- FWCI
- 0.72
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Gastroenterology and Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Gastroenterology › Gastroesophageal reflux and treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- domperidone, diabetic gastroparesis, drug efficacy, gastric emptying, symptom improvement, hospitalization, study quality, level of evidence
- MeSH terms
- Clinical Trials as Topic, Domperidone, Humans, United States, Treatment Outcome, Gastroparesis, Diabetes Complications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
